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The receptors involved in the bronchoconstnction evoked in vivo
by intravenous administration to the anesthetized guinea pig of
serotonin and serotonin-related agonists have been examined in
this study. Animals were pretreated with indomethacin and (±)-
propranolol to inhibit cyclooxygenase and beta adrenergic recep-
tors, respectively, and pulmonary parameters were obtained with
a Buxco pulmonary mechanics computer. Dose-dependent in-
creases in pulmonary resistance and decreases in dynamic lung
compliance were produced by serotonin, 2-methyl-serotonin,
5-methoxy-tryptamine, a-methyl-serotonin, 5-carboxamidotryp-
tamine, and m-trifluoromethylphenylpiperazine (TFMPP). Re-
sponses to all agonists except 2-methyl-serotonin, a selective
5-hydroxytryptamine3 (5-HT3) agonist, were antagonized by
the 5-HT2 antagonists, LY53857 and ketanserin. Zacopnde, 1
and 1 0 mg/kg, a selective 5-HT3 antagonist, blocked responses
to 2-methyl-serotonin. A maximally effective dose of LY53857 (1
mg/kg) produced larger shifts of the dose-response curves to
serotonin, 5-methoxytryptamine and a-methyl-serotonin than did
a maximally effective dose of ketansenn (1 mg/kg). Thiorphan,
1 0 mg/kg, an inhibitor of neutral endopeptidase, potentiated 2-
methyl-serotonin and, when studied in the presence of LY53857,
also potentiated serotonin, 5-methoxytryptamine and TFMPP.
After thiorphan and LY53857, responses to serotonin, but not
5-methoxytryptamine or TFMPP, were blocked by zacopnde.
Capsaicin pretreatment of the animals resulted in nghtward shifts
of the dose-response curves to serotonin, 2-methyl-serotonin
and TFMPP, but not to 5-methoxytryptamine or a-methyl-sero-
tonin. Potentiation by thiorphan and antagonism by zacopride of
responses to serotonin were still evident after capsaicin pretreat-
ment. The data implicate involvement of 5-HT1-iike, 5-HT2 and
5-HT3 receptors in serotonin-induced pulmonary responses in
the guinea pig. Another 5-HT receptor subtype, unclassified at
present, is suggested on the basis of quantitative differences in
maximum antagonism by LY53857 and ketanserin. Release of
endogenous peptides (possibly tachykinins) from capsaicin-sen-
sitive C-fibers appears to result from activation of 5-HT1-like and
5-HT3 receptors. Release of bronchospastic peptide(s) from cap-
saicin-insensitive sites may also result from activation of 5-HT3
and unclassified serotonin receptor subtypes.
The ability of serotonin to produce bronchoconstriction in
vivo has been attributed to direct and indirect mechanisms
(e.g., Comroe et at., 1953; Islam et at., 1974; Konzett, 1956;
Krell et at., 1976; Peterson and Biggs, 1981), but classification
of the receptors involved in these actions of the agonist has
received little attention.
Since the initial classification (Gaddum and Picarelli, 1957)
and subsequent reclassifications (Bradley et at., 1986; Peroutka
and Snyder, 1979) of receptors for serotonin, the list of putative
subtypes based on radioligand binding or functional studies has
continued to grow (e.g., Connell and Wallis, 1989; Dumuis et
at., 1988; Hoyer et at., 1985; Leonhardt et at., 1989; Mawe et at.,
1986; Surprenant and Crist, 1988; Xiong and Nelson, 1989). At
least four general categories of receptors for serotonin have
been postulated to exist, namely, the 5-HT1, 5-HT2, 5-HT3 and
5-HT4 subtypes. Variants of each subtype appear also to occur.
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Even while the status of serotonin receptor subclassification
continues to evolve, a few seemingly selective agonists and
antagonists have appeared, but their bronchoconstrictor ac-
tions have not been extensively investigated.
This communication describes results of in vivo studies using
several serotonin receptor agonists and antagonists. The ex-
periments were designed to provide information about sero-
tonin receptor subtypes and their potential for mediating direct
vs. indirect bronchoconstriction in the guinea pig.
Methods
Male albino guinea pigs weighing 350 to 600 g were anesthetized
with urethane (1.5 g/kg, i.p.) and placed on a heating pad to maintain
body temperature at 37CC. Temperature was monitored via a rectal
probe on a YSI tele-thermometer. The carotid artery and jugular vein
were cannulated for monitoring animal survival via blood pressure and
for drug administration, respectively. The trachea was cannulated and
the cannula connected to a heated Fleisch (no. 0000) pneumotacho-
ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; 5-CT, 5-carboxamidotryptamine; TFMPP, m-trifiuoromethylphenylpiperazine; GL, airway conductance;
NEP, neutral endopeptidase; R, pulmonary resistance.
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graph. Airflow was measured via a Validyn differential pressure trans-
ducer (model MP45-14) attached to the pneumotachograph. Transpul-
monary pressure was measured via a Validyn differential pressure
transducer (model 45-24) connected between a sidearm of the tracheal
cannula and a 16-gauge intrapleural needle placed between the fifth
and sixth ribs. The needle contained several holes near the tip to
prevent occlusion during respiration. Air flow and transpulmonary
pressure were recorded with a Buxco Pulmonary Mechanics Computer
(model 6; Buxco Electronics, Sharon, CT). The computer calculated
R and dynamic lung compliance on a breath-by-breath basis. Analog
signals from the computer were digitized by a Buxco Analog converter
and printed on a Texas Instruments (model 600) printer. Animals were
allowed to stabilize for 5 to 10 mm following surgical manipulations
before beginning drug administration.
All drugs were administered intravenously in volumes of 1 ml/kg.
Dose-response effects of serotonin and other agonists were obtained by
giving bolus injections of the agonist at 10-mm intervals. This was
adequate time for pulmonary parameters to return to pre-agonist levels.
Doses of agonists (moles/kg) were increased in increments of about 3-
fold until maximum response was achieved, the maximum dose based
on availability limitations wan administered or death of the animal
ensued. Surviving animals were euthanized by administration of an
overdose of urethane. Maximum response was defined as zero conduct-
ance (GL, the reciprocal of Re). Peak values of GL were expressed as a
percentage of the baseline value before agonist and ED values calcu-
lated as the dose resulting in a reduction of GL to 50% of baseline. In
addition to serotonin, the following agonista were quantified in this
study: 2-methyl-serotonin, 5-methoxytryptamine, a-methyl-serotonin,
5-CT, TFMPP, substance P and neurokinin A. Only one dose-response
curve was obtained in each animal. All EDo values were converted to
the negative logarithm and expressed as -log ED,o. In some cases, -log
ED40 and -log ED values were also quantified as measures of the
position of the dose-response curve along the log dose axis. In general,
the dynamic lung compliance responses mirrored the R responses
induced by the several agonists employed in this study.
In order to minimize indirect influences on pulmonary responses
resulting from formation of cyclooxygenase products (Mitchell and
Adcock, 1988; Bakhle and Smith, 1977) and activation of beta adrener-
gic receptors (Innes, 1962; Pluchino, 1972; Freeman et at., 1981), all
animals were pretreated with indomethacin, 10 mg/kg, and (±)-pro-
pranolol, 0.5 mg/kg, 20 and 15 mm, respectively, before agonist admin-
istration. In preliminary studies, it was found that these pretreatments
resulted in a leftward shift (approximately 0.5 log unit, P < .05) of the
serotonin dose-response curve (-log EDM values were: without pre-
treatment, 7.41 ± 0.09, n = 8; with pretreatment, 7.90 ± 0.03, n = 8).
Other drug pretreatments employed in this study were as follows:
LY53857 (5-HT2 antagonist), 50 mm; thiorphan (NEP inhibitor), 10
rain; and ketanserin (5-HT2 antagonist), mianserin (5-HT,-like and 5-
HT2 antagonist), zacopride (5-HT3 antagonist), atropine (cholinergic
muscarinic antagonist) and pyrilamine (histamine H1 antagonist), 25
to 30 mm before beginning agonist administration. Times of adminis-
tration were based on demonstration of established effects in prelimi-
nary experiments and from published information (e.g., Buckner et a!.,
1985; Krell et a!., 1987). None ofthese drugs altered baseline pulmonary
parameters at the doses used in these studies. After indomethacin and
propranolol pretreatment, the baseline resistance values before begin-
ning injections of serotonin averaged 0.145 ± 0.011 cm H20/ml/sec
(n=8).
For some experiment8, animals were pretreated with capsaicin to
deplete sensory neurons ofneuropeptides (reviewed by Buck and Burks,
1986). A total dose of 125 mg/kg of capsaicin was administered subcu-
taneously over a 2-day period according to the protocol described by
Gamse et at. (1981). Control animals received capsaicin vehicle (see
below). All animals in these 2 groups received theophylline, 5 mg/kg,
i.p., 30 mm before each dose of capsaicin or vehicle, as a means of
minimizing bronchospasm. Animals were used in dose-response studies
between 6 and 14 days after the last day of capsaicin or vehicle
administration. There were no differences in baseline pulmonary pa-
rameters between these 2 groups of animals. Before beginning study
with a capsaicin-pretreated animal, the acute pulmonary response to
capsaicin, 3 x iO moles/kg, i.v., was determined. If an increase in R
was seen with this dose of capsaicin, the animal was not used for these
experiments. This dose was found, in preliminary studies, to evoke
maximum decreases in GL in normal (non-capsaicin-pretreated) guinea
pigs.
Analyses. Means and S.E.M.s were calculated for values in each
experimental series. Statistical differences between means were deter-
mined using analysis of variance or Student’s t test, and P < .05 was
considered statistically significant.
Drugs and solutions. The following drugs were used: indometha-
cm, (±)-propranolol hydrochloride, 5-hydroxytryptamine hydrochlo-
ride (serotonin), atropine sulfate, pyrilamine maleate, substance P, a-
neurokinin (neurokinin A), 8-methyl-N-vanillyl-6-nonenamide (98%,
capsaicin), tris(hydroxymethyl)aminomethane (Trizma base) and
thiorphan (Sigma Chemical Co., St. Louis, MO); theophylline (Calbi-
ochem, San Diego, CA); urethane (Aldrich Chemical Co., Inc., Milwau-
kee, WI); 2-methyl-5-hydroxytryptamine maleate (2-methyl-sero-
tonin), a-methyl-5-hydroxytryptamine maleate (a-methyl-serotonin),
5-methoxytryptamine hydrochloride, TFMPP hydrochloride, 5-CT ma-
leate, ketanserin tartrate and mianserin hydrochloride (Research Bio-
chemicals Inc., Natick, MA). LY53857 and zacopride hydrochloride
were kindly supplied by Eli Lilly and Co., Indianapolis, IN, and A. H.
Robins Co., Inc., Richmond, VA, respectively.
Indomethacin was prepared in 0.9% sodium chloride containing 0.1
M Trizma base; thiorphan in 0.9% sodium chloride containing 10%
PEG400; and capsaicin in 10% (v/v) 95% ethanol, 10% (v/v) Tween
80 and 80% (v/v) normal saline. Other drugs were dissolved and diluted
in 0.9% sodium chloride. The vehicles had no influence on agonist
responses and data with and without vehicle were pooled when
appropriate.
Results
Effects of 5-HT2 receptor antagonists. Dose-dependent
antagonism of serotonin-induced decreases in GL was obtained
after pretreatment with LY53857 (fig. 1). When measured at
the ED56 level, a sharp decrease in the rightward progression
of the dose-response curve was observed between 0.1 and 1 mg/
kg doses of LY53857. There was not a statistically significant
difference in -log ED56 values for serotonin using these 2 doses
Fig. 1. Log dose-response effects of serotonin for causing decreases in
GL in anesthetized guinea pigs studied without (control) and with the
designated doses of LY53857. All animals were pretreated with indo-
methacin and propranolol (see Methods”). The -log ED ± S.E.M.
values for serotonin were 7.85 ± 0.05 (n = 1 6), 7.28 ± 0.08 (n = 4),
5.74 ± 0.14 (n = 10) and 5.30 ± 0.14 (n = 19) in the absence of
antagonist and after administration of LY53857, 0.01 , 0.1 and 1 mg/kg,
respectively. Values for the latter two doses of LY53857 are not statis-
tically different (P > .05). Vertical lines represent S.E.M.
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of the antagonist (fig. 1). In an additional group (n = 8) of
animals, 2 i.v. doses of LY53857, 1 mg/kg each, the second
administered 5 mm before serotonin, did not result in a further
shift of the dose-response curve from that observed after a
single injection of this dose (given 50 mm before serotonin) of
the antagonist (P > .05, data not shown). Therefore, the effect
of the antagonist appeared stable for the duration of the exper-
iment and all subsequent studies were conducted using the
single dose (1 mg/kg) administered 50 mm before agonist.
Ketanserin also produced dose-dependent rightward shifts of
the serotonin dose-response curve and the rightward progres-
sion reached maximum at 1 mg/kg of the antagonist (table 1).
The magnitude of the shift of the serotonin dose-response curve
was similar when this dose of ketanserin was given 50 mm
before (n = 9) or twice (30 and 5 mm) before (n = 4) beginning
agonist administration (P > .05, data not shown). Therefore,
all subsequent dose-response curves were obtained beginning
30 mm after administration of ketanserin.
Mianserin, an antagonist claimed to have approximately
equal binding affinity for 5-HT2 and 5-HT1 receptors (Hoyer
et aL, 1985), at 3 mg/kg, resulted in a similar degree of rightward
shift of the serotonin dose-response curve as the maximum
produced by ketanserin (table 1). Combination of ketanserin,
1 mg/kg, and mianserin, 3 mg/kg, did not result in a larger
shift (P > .05) than either antagonist alone (table 1).
The -log ED,o values for serotonin and several other related
agonists without and with maximally effective doses (1 mg/kg)
of LY53857 and ketanserin against serotonin are summarized
in table 2. Effects of all but 2-methyl-serotonin (a selective
5HT3 5onist studied after thiorphan administration, see be-
low) were blocked by the 2 antagonists. When serotonin, a-
methyl-serotonin and 5-methoxytryptamine were agonists,
LY53857 shifted the dose-response curves to a larger degree
than did ketanserin. Even though combinations of ketanserin
and mianserin resulted in a slight further shift of the 5-meth-
oxytryptamine dose-response curve when compared with that
seen after 1 mg/kg of ketanserin alone (table 1), the magnitude
of the antagonism by LY53857 of this agonist remained larger.
For TFMPP and 5-CT (5-HT1-like receptor agonists), both
antagonists shifted the dose-response curves to about the same
degree (fig. 2). Doses of the latter agonist were not increased
TABLE 1
above iO- moles/kg due to limitations on availability and
effective dose values were not calculable after antagonist ad-
ministration. TFMPP exhibited a biphasic dose-response curve
and antagonism by LY53857, and ketanserin was observed only
for responses at smaller doses of the agonist (fig. 2). Mianserin,
3 mg/kg, did not further affect the dose-response curve to
TFMPP when examined in the presence of ketanserin, 1 mg/
kg (table 1).
Effects of thiorphan. As an inhibitor of NEP (Thorsett
and Wyvratt, 1987), thiorphan would be predicted to potentiate
responses produced by peptides that are substrates for the
enzyme. Thiorphan produced dose-dependent potentiation of
substance P, which appeared maximum with a dose of 10 mg/
kg of inhibitor (table 3). A similar magnitude of potentiation
of neurokinin A was observed with 10 mg/kg of thiorphan
(table 3), and this dose was used in all subsequent studies.
Thiorphan, 10 mg/kg, also potentiated serotonin when stud-
ied in the presence of LY53857 and ketanserin (table 2). Poten-
tiation by thiorphan of serotonin was not observed in the
absence of the 5-HT2 antagonists.
In the presence of LY53857 or ketanserin, other serotonergic
agonists, except for a-methyl-serotonin, were also potentiated
by thiorphan (table 2). For 2-methyl-serotonin, enhancement
was seen in the absence of these antagonists (fig. 3). Without
thiorphan, responses to this agonist reached 50% in only four
of the eight (40% was reached in six) animals studied. There-
fore, -log effective dose values under this condition could not
be accurately quantified. All other experiments with 2-methyl-
serotonin were conducted after thiorphan administration and
sensitivities to the agonist were determined by calculation of
-log ED40 values.
Effects of zacopride. The 5-HT3 antagonist, zacopride,
appeared to caused dose-dependent antagonism of 2-methyl-
serotonin, despite availability limitations on the agonist dose
to a maximum of iO moles/kg (fig. 3). Zacopride also antag-
onized serotonin when examined in the absence, but not in the
presence of LY53857 and ketanserin (table 2). Antagonism by
zacopride, 1 mg/kg, of 5-methoxytryptamine without and with
atropine pretreatment was also observed in the absence of 5-
HT2 antagonists (table 2, see below). However, when thiorphan
was also administered, antagonism by zacopride of serotonin
Summary of effects of ketanserin and mianserin on guinea pig pulmonary responses to serotonin and related agonists
Ketanserin
Agonist(Antagonist treatment) No Ketanserin
0.3mg/kg 1.0 mg/kg 3.0 mg/kg
-‘og ED, ± S.E.M.
Serotonin
(None) 7.85 ± 0.05 (16)L 6.42 ± 0.07 (8)’ 6.19 ± 0.07 (9 5.95 ± 0.18(8)
(Mianserin, 3 mg/kg) 5.93 ± 0.12 (9)’ 5.85 ± 0.08 (8)
TFMPP
(None) 5.85±0.13(10) 4.95±0.06(7r
(Mianserin, 3 mg/kg) 4.89 ± 0.06 (9)
5-Methoxytryptamine
(None) 7.94 ± 0.09 (8) 5.53 ± 0.12 (8T 5.18 ± 0.06 (8T
(Mianserin, 3 mg/kg) 5.11 ± 0.06 (8)” 5.03 ± 0.16(6)
. Values represent negative logarithms ± S.E.M.s of the dose (moles/kg) of agonist required to decrease G. to 50% of baseline. All experiments were cOnduCted after
administration of indomethacin and propranolol (see Methods).
a The number of animals studied in each group is denoted in parentheses.
C Denotes a value that is statistically different (P < .05) from that preceding in each row for the same agonist.
d Denotes a value that is statistically different (P < .05) from that preceding in each column for the same agonist.
I Responses obtained also in the presence of thiorphan, 10 mg/kg.
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Summary of effects of LY53857, ketanserin, zacopride and thiorphan on guinea-pig pulmonary responses to serotonin and related
agonists
Agont(Zacopflde i.v dose) Contr WJi Thorphai
With LY53857’ Wtii Ketanseiin’





7.85 ± 0.05 (16)’
7.74 ± 0.04 (8)’
7.04 ± 0.06 (9)’
7.98 ± 0.07 (10)
7.61 ± 0.07 (8)’
7.02 ± 0.08 (8)’
-kg ED, ± S.E.M.b
5.30 ± 0.14 (19) 6.20 ± 0.04 (8)d
4.99 ± 0.10 (8) 5.08 ± 0.17 (8)’
5.35 ± 0.15 (6) 5.68 ± 0.18 (8)’
6.19 ± 0.07 (9)”
6.32 ± 0.14 (9
6.66 ± 0.1 1 (8r




7.94 ± 0.09 (8)
7.39 ± 0.1 2 (3)’9
7.98 ± 0.07 (7) 4.45 ± 0.10 (7) 4.93 ± 0.12 (5)C
4.94 ± 0.1 1 (8)
5.53 ± 0.12 (8
5.68 ± 0.1 7 (7)
5.50 ± 0.12 (9
a-Methyl-serotonin
(No zacopride) 8.02 ± 0.04 (8) 8.18 ± 0.05 (8 5.51 ± 0.12 (8) 5.58 ± 0.08 (8) 6.28 ± 0.14 (8 6.22 ± 0.10 (9
5-CT




5.49 ± 0.28 (7 5.85 ± 0.13 (10 4.69 ± 0.06 (8) 4.91 ± 0.07 (8Y
4.86 ± 0.07 (9)
4.65 ± 0.07 (9) 4.95 ± 0.06 (7Y’
2-Methyl-serotonin’
(No zacopride) 6.09 ± 0.1 1 (1 0) 6.36 ± 0.08 (6) 6.36 ± 0.1 2 (8)
a Responses were obtained after pretreatment of the animals with LY53857 or ketansenn, 1 mg/kg, iv.
b Values represent negative logarithms ± S.E.M.s of the dose (moles/kg) of agonist required to decrease G,. to 50% of baseline unless indicated otherwise. Guinea
pigs were studd without (control) or with thiorphan, 10 mg/kg, pretreetment. M experiments were COnduCted after administration of indomethacan and propranolol (see
Methods).
C The number of animals studied in each group is denoted in parentheses.
d Denotes a statistically significant (P < .05) effect of thiorphan in each antagonist treatment group.
I Denotes a statistically significant (P < .05) difference in -log ED, value between LY53857 and ketanserin pretreatments under the same condition of thiorphan
treatment.
, Denotes a statistically significant (P < .05) effect of zacopride when compared with the value obtained without zacopride.
a The -log ED, value for 5-methoxytryptamine after zacopride studied with atropine pretreatment was 7.26 ± 0.13 (n = 4) and statistically different (P < .05) from
the value obtained after atropine alone (Table 5).
C NC = not calculable since the magnitude of response at the maximum dose used did not attain an appropriate level.
I The -log ED, values for TFMPP in control and thiorphan-treated groups without antagonist treatment were 4.92 ± 0.17 and 5.45 ± 0.16. respectively (P < .05).
I Numbers represent -log EDo values.
100- TFMPP
i%;#{188}:.,\.
iO_7 1O iO5 1O 1O iO 10’ 10’
Agonist (moqkg)
Fig. 2. Log dose-response effects of TFMPP (left panel) and 5-CT (right
panel) for causing decreases in G. in anesthetized guinea pigs studied
without (control) and with doses of LY53857 and ketansenn that caused
maximum shifts of the dose-response curve for serotonin. All animals
were pretreated with indomethacin and propranolol (see Methcs) The
-log effective dose values for TFMPP and 5-CT are summarized in table
2. A level of response adequate to calculate effective dose values for 5-
CT was not attained after LY53857 (n = 7) and ketansenn (n = 6).
Vertical lines represent S.E.M.
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5-CT
was seen in the presence of the two 5-HT2 antagonists. In the
presence of LY53857 (or ketanserin) and thiorphan, zacopride
did not antagonize responses to 5-methoxytryptamine or
TFMPP (table 2). Zacopride also did not alter the dose-re-
sponse effects of substance P or neurokinin A (table 3). Also,
when studied in the presence of thiorphan, neither LY53857
nor ketanserin altered responses to the tachykinins (table 3).
Effects of capsaicin pretreatment. Pretreatment with
capsaicin resulted in antagonism of serotonin when examined
in the presence, but not in the absence of LY53857 (fig. 4, table
4). Similar results were obtained when responses to serotonin
were examined after thiorphan administration. It should be
noted that, in the presence of LY53857, thiorphan potentiated
serotonin with or without capsaicin pretreatment (fig. 4, table
4). Furthermore, even after capsaicin pretreatment, antagonism
by zacopride was evident (table 4).
Inhibition of responses to 2-methyl-serotonin and TFMPP
was also observed after pretreatment of the animals with cap-
saicin (fig. 5). However, capsaicin pretreatment did not alter
responses to 5-methoxytryptamine (fig. 5, table 4) or to a-
methyl-serotonin (table 4).
Capsaicin pretreatment also did not alter the dose-response
effects of substance P in three animals (-log ED of 10.14 ±
0.09) or of neurokinin A in two animals (-log ED,o of 11.02
and 10.77) when examined after thiorphan, 10 mg/kg.
Effects of atropine and pyrilamine. Neither muscarinic
receptor nor histamine H1 receptor blockade markedly altered
responses to agonists employed in this study (table 5). Antag-
onism by pyrilamine, 2 mg/kg, of responses to a-methyl-sero-
tonin was observed when examined in the presence of LY53857.
A similar degree of blockade by atropine, 1 mg/kg, of 5-meth-
oxytryptamine and a-methyl-serotonin was seen in the absence,
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TABLE 3
Summary of effect s of thiorphan, LY53 857, ketanserln and z acopride on guinea -pig pulmonary res ponses to substance P and neurokinin A





9.36 ± 0.05 (24
9.80 ± 0.06 (1 7)
10.12 ± 0.08 (7
1 0.78 ± 0.09 (1 1 )
-log ED,4,± S.E.M.C
10.22 ± 0.07 (7)
1 1 .04 ± 0.07 (4)
10.15 ± 0.09 (8)
10.91 ± 0.07 (4)
10.17 ± 0.09 (7) 10.18 ± 0.12(6)
10.97 ± 0.1 1 (8) 10.69 ± 0.03(7)
obtained without and with administration of vehicle for thiorphan (10% PEG400) were pooledsince there were no statistically significant changes caused by
this pretreatment.
bA maximum degree of leftward shift by thiorphan of substance P was produced by 10 mg/kg. The -log ED,, values for substance P after 1, 3 and 30 mg/kg of
thiorphanwere9.78±0.06(n=8),9.98±0.11(n=8)andlo.17±0.12(n=8).
C Values represent negative logarithms ± S.E.M.s of the dose (moles/kg) of agonist required to decrease 6,. to 50% of baseline. Guinea pigs were studied without
(control) or with thiorphan, 10 mg/kg, pretreatment. Dose-response effects with LY53857, 1 mg/kg, ketansenn, 1 mg/kg, and the two designated doses of zacopride
were obtained after thiorphan pretreatment. AS experiments were conducted after administration of indomethacin and propranolol (see Methods).
d The number of animals studied in each group is denoted in parentheses.
I Denotes a value for each agonist with thiorphan that is statistically different (P < .05) from that Obtained in the control group (without thiorphan). Values Obtained







10-s iO io’ iO
2-Methyl-Serotonin (mol/kg)
Fig. 3. Log dose-response effects of 2-methyl-serotonin for causing
decreases in G. in aflsthatizOd guinea pigs studied without (control, n
= 8) and with thiorphan, 1 0 mg/kg (n = 1 0). Animals that received
thiorphan were also examined after administration of zacopnde, 1 (n =
8) and 10 (n = 8) mg/kg. All animals were pretreated with indomethacin
and propranolol (see “Methods”). Vertical lines represent S.E.M.
Discussion
The results of this study provide information about the
subtypes of 5-HT receptors mediating bronchoconstriction in
the guinea pig as well as potential sites through which these
responses are elicited. Indirect components that could modulate
serotonin-induced bronchoconstriction through cyclooxygenase
product formation and beta adrenergic receptor activation were
minimized by pretreatment of the animals with indomethacin
and propranolol, respectively. The consequences of ongoing
cyclooxygenase activity would be expected to be balanced by
the extent to which bronchodilator and bronchoconstrictor
products are formed under the several experimental conditions,
whereas catecholamine release uniformly results in functional
antagonism of responses to bronchoconstrictor substances (Or-
ehek, 1981). Therefore, these pretreatments are important to
quantitation of the more direct results of bronchospastic recep-
tor activation. The extent to which antagonism by propranolol
of5-HT1-like receptors (Middlemiss, 1984; Oksenberg and Per-
outka, 1988) occurred in these studies is not known.
In light of the large shift of the dose-response curve produced
by LY53857 and ketanserin, the major action of serotonin in
inducing decreases in GL appears to result from activation of
receptors of the 5-HT2 subtype. Furthermore, since studies
with isolated airway smooth muscle have demonstrated the
dominance of 5-HT2 receptor-mediated contractions (Cohen et
Fig. 4. Log dose-response effects of serotonin for causing decreases In
OL in anesthetized guinea pigs treated with capsaicin or capsaicin vehicle
as deScribed in Methods. Allanimals were pretreated with indomethacin
and propranolol and results shown in the lower panel were obtained in
animals that also received thiorphan, 1 0 mg/kg. Studies were COnduCted
in the absence (#{149})and presence of LY53857, 1 mg/kg. The -log ED
values for serotonin obtained in these experiments are summarized in
table 4. Vertical lines represent S.E.M.
at., 1985; Selig et at., 1988; Van Nueten et aL, 1982), it is
reasonable to suggest that contraction of airway smooth muscle
via activation of these receptors in vivo is responsible for
decreases in GL evoked by serotonin in the absence of the 5-
HT2 receptor antagonists. Since the degree of additional block-
ade by LY53857 and ketanserin diminished with dose of antag-
onist (and the shift of the serotonin dose-response curve
reached a maximum under the influence of both drugs), recep-
tors other than the 5-HT2 subtype appear to be activated by
the larger doses of serotonin.
Results with several so-called selective agonists suggest that
decreases in GL in the guinea pig can also be elicited by
activation of receptors of 5-HT1-like and 5-HT3 subtypes. Of
these agonists, the most selective appears to be 2-methyl-
serotonin since responses to this 5-HT3 agonist (Richardson et
at., 1985) were unaltered by LY53857 or ketanserin, and effec-
tively blocked by zacopride, a 5-HT3 receptor antagonist
(Barnes et aL, 1988; Smith et at., 1988). Zacopride also appears
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-109 ED,,, ± S.E.M.d
Serotonin
(None) 7.91 ± 0.10 (8)’ 7.85 ± 0.07 (8) 7.98 ± 0.06 (8) 7.85 ± 0.12 (6)
(LY53857, 1 mg/kg)
(LY53857, 1 mg/kg, and
5.60 ± 0.20 (9) 4.54 ± 0.12 (8)’ 6.24 ± 0.1 1 (9)
5.25 ± 0.13 (7r
5.20 ± 0.13 (7)’9
4.55 ± 0.10 (8)’’
Zacopride, 1 mg/kg)
5-Methoxytryptamine
(LY53857, 1 mg/kg) 4.50 ± 0.14 (4) 4.64 ± 0.10 (8)
a-Methyl-serotonin
(LY53857, 1 mg/kg) 5.40 ± 0.09 (4) 5.49 ± 0.10(4)
a Sham-treatment consisted of subcutaneous administration of the capsaicin vehicle using the same injection schedule as that for the active ingredient.
U Capsaicin treatment consisted of subcutaneous administration of capsaicin according to the schedule provided in Methods.
C All experiments in these groups were COndUCted after administration of thiorphan, 10 mg/kg.
U Values represent negative logarithms ± S.E.M.s of the dose (moles/kg) of serotonin required to decrease GL to 50% of baseline. All experiments were conducted
after administration of indomethacin and propranolol (see Methods’).
I The number of animals studied ki each group is denoted in parentheses.
I Denotes a statistically significant (P < .05) difference in -log ED,,, values for agonist between sham-treated and capsaicin-treated groups with each antagonist
treatment.
9 Denotes a statistically significant (P < .05) change in -log ED,, value for serotonin resulting from thiorphan administration to sham-treated or capsaicin-treated
animals studied in the presence of LY53857.
h Denotes a statistically significant (P < .05) change in -log EDU, value for serotonin resulting from zacopride administration to sham-treated or capsaicin-treated
animals studied in the presence of thiorphan and LY53857.
Sham-Treated
. Capsaicin-Treated
p ..i .J .1 . . . ..I
10-e i0- 10-#{149}i0- 10-’ 10’ 10’ 10 10’ 10’
Agonist (mo$/kg)
Fig. 5. Log dose-response effects of 2-methyl-serotonin, TFMPP and 5-
methoxytryptamine for causing decreases in G. in anesthetized guinea
pigs treated with capsaicin or capsaicin vehicle as described in “Meth
ods:’ All animals were pretreated with indomethacin and propranolol and
those challenged with 2-methyl-serotonin and TFMPP also received
thiorphan, 10 mg/kg. Responses to TFMPP and 5-methoxytryptamine
were obtained after treatment with LY53857, 1 mg/kg. The -log EDse
values for 5-methoxytryptamine are summarized in table 4. The -log
EDsa values for 2-methyl-serotonin and TFMPP in the sham-treated
animals were 6.12 ± 0.08 (n = 8) and 4.85 ± 0.08 (n = 6), respectively.
The effective dose values in the capsaicin-treated groups for 2-methyl-
serotonin (n = 8) and TFMPP (n = 5) were not calculable since the
magnitude of response at the maximum dose of agonist did not attain
an appropriate level. Vertical lines represent S.E.M.
the doses used in these studies, this antagonist shifted to the
right the dose-response curve to serotonin and 5-methoxytryp-
tamine in the absence of other 5-HT2 antagonists (LY53857
and ketanserin). However, under conditions in which the 5-
HT2 receptors appear maximally antagonized by LY53857 or
ketanserin, zacopride did not cause additional blockade of
serotonin or of 5-methoxytryptamine when studied in the ab-
sence and presence of thiorphan, respectively. Thiorphan ad-
ministration appears to optimize conditions under which a 5-
HT3 component of the serotonin response, as evidenced by
zacopride blockade, can be observed.
Blockade by LY53857 and ketanserin of pulmonary re-
sponses to 5-CT and TFMPP, both usually classified as selec-
tive for 5-HT1-like receptors (Schoeffter and Hoyer, 1989;
Trevethick et at., 1986), suggests that these agonists are capable
of activating 5-HT2 receptors to cause decreases in GL. The
latter appears to exert “partial” agonist activity at these recep-
tors since the dose-response curve was biphasic and responses
at only the smaller doses were blocked by the 5-HT2 antago-
nists. This interpretation of the action of TFMPP is consistent
with observations reported for isolated tissue experiments
(Cohen and Fuller, 1983). Resistance to blockade by LY53857
and ketanserin of responses to larger doses of TFMPP indicates
an action of the agonist on receptors other than 5-HT2 under
these experimental conditions. Since the effects of TFMPP
occurring after maximally effective doses of LY53857 and ke-
tanserin were not altered by zacopride, there does not appear
to be a 5-HT3 component to the action of this agonist. There-
fore, by the process of exclusion, it appears that activation of a
5-HT1-like receptor can lead to a decrease in GL in the guinea
pig. The possible nonselective action of TFMPP at several of
the 5-HT1-like receptors (Schoeffter and Hoyer, 1989) pre-
cludes a receptor subtype assignment for the pulmonary re-
sponses evoked by this agonist after 5-HT2 blockade. Moreover,
in the absence of an effective 5-HT1-like receptor antagonist
against TFMPP, it remains possible that the non-5-HT2 effects
observed with this agonist are unrelated to activation of sero-
tonin receptors. The ability of TFMPP to act as an antagonist
of alpha adrenergic receptors (Cohen et at., 1983) is not likely
to be responsible for bronchoconstriction caused by large doses
of the compound since other antagonists at these receptors
(e.g., phentolamine; Buckner et at., 1985) do not exert similar
effects in normal guinea pigs. Furthermore, the bronchospasm
does not appear to result from agonist actions at alpha receptors
since phentolamine, 3 mg/kg, did not block the non-5-HT2
actions of TFMPP (unpublished data). Activation of 5-HT2
receptors by 5-CT-induced release of platelet serotonin has
been reported (Wright and Angus, 1989), but whether this
mechanism accounts for ketanserin- and LY53857-sensitive
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TABLE 5
Summary of effects of atropine and pyrilami ne on guinea-pig pulmonary re sponses to serotonin and oth or agonists





7.98 ± 0.07 (lOr
6.20 ± 0.04 (8)
6.66 ± 0.1 1 (8)
-log ED,,, ± S.E.M.C
7.91 ± 0.07 (8)
6.04 ± 0.21 (8)
6.77 ± 0.05 (7)
7.90 ± 0.06(8)






7.94 ± 0.09 (8)
4.93 ± 0.1 2 (8)
5.53 ± 0.12 (8)
7.59 ± 0.06 (9)’
4.98 ± 0.1 6 (8)
5.38 ± 0.06 (7)
7.74 ± 0.04(6)





8.02 ± 0.03 (8)
5.51 ± 0.12 (8)
7.78 ± 0.03 (6
5.43 ± 0.09 (4)
7.91 ± 0.03(7)
5.18 ± 0.07 (7)
TFMPP
(Ketansenn, 1 mg/kg) 4.95 ± 0.06 (7) 4.86 ± 0.02 (4) 4.97 ± 0.07 (6)
2-Methyl-serotonin’
(None) 6.09 ± 0.1 1 (10) 6.05 ± 0.10 (7) 6.16 ± 0.21 (8)
Substance P
(NOne’) 9.36±0.05(24) 9.28±0.15(8) 9.31 ± 0.06(8)
Neurokinin A
(None’) 9.80 ± 0.06 (17) 9.90 ± 0.05 (8)
a All experiments in rows designated with an a were COnduCted without thiorphan administration. Lkiess so designated, animals were studied after administration of
thiorphan, 10 mg/kg.
b Control values are reproduced from Tables 1 and 2 for comparative purposes.
C Values represent negative logarithms ± S.E.M.s of the dose (moles/kg) of agonist required to decrease G to 50% of baseline unless indicated otherwise. Guinea
pigs were studied without (controO or with atropine, 1 mg/kg, or pyrilamine, 2 mg/kg, pretreatment. M experiments were conducted after adminiStratiOn of Indomethacin
and propranolol (see ‘Methods).
dThe number of animals in each group is denoted in parentheses.
. Denotes a statistically significant (P < .05) difference between values Obtained in control and atropine- or pyrilamine-trated animals.
I Numbers for this agonist represent -log ED values.
U Experiments were cOndUCted after administration of a combination of atropine and pyrilamine.
responses to this agonist in the present studies is not known.
Ifrelease ofserotonin was the only action of5-CT, a differential
degree of blockade by the two 5-HT2 antagonists might have
been expected.
The agonists 5-methoxytryptamine and a-methyl-serotonin
also appear to have a dominant 5-HT2 receptor action in light
of the substantial degree of blockade by LY53857 and ketan-
serin of their pulmonary effects. The absence of an atropine-
sensitive component in the action of these agonists after 5-HT2
receptor blockade implicates 5-HT2 receptors in mediation of
their small indirect cholinergic effects. The larger magnitude
of rightward shift by LY53857 of the dose-response curves for
these agonists is similar to that seen when serotonin was used
as an agonist and indicates the possibility that an unclassified
receptor is involved in the action of these agonists. Since 5-
methoxytryptamine and a-methyl-serotonin have been impli-
cated as acting at 5-HT1 subtypes (e.g., Hoyer et at., 1989;
Ismaiel et at., 1990; Schlicker et a!., 1989) and a 5-HT4 receptor
(Craig and Clarke, 1990; Dumuis et a!., 1988), it is conceivable
that LY53857 causes larger blockade, at maximum, than ketan-
serin because of antagonism of one or both of these receptor
subtypes. Alternatively, the difference might reflect the exist-
ence of putative 5-HT2 receptor subtypes (Killam et aL, 1990).
It does not appear likely that divergent directions of allosteric
regulation of the 5-HT2 receptor (Kaumann, 1989) can account
for the difference in blockade by the two antagonists since
dose-response curves to TFMPP and 5-CT were not differen-
tially altered.
Recent evidence suggests that LY53857 also has affinity for
the 5-HT1 subtype (Hoyer et aL, 1989). It does not seem likely,
however, that the quantitative difference in magnitude of an-
tagonism exerted by LY53857 vs. ketanserin is due to an
additional action by the former drug on 5-HT1 receptors since
mianserin (with similar binding affinities for the 5-HT2 and 5-
HT1 subtypes; Hoyer et at., 1985) did not cause further antag-
onism of serotonin in the presence of ketanserin. Also, mian-
serin alone caused a similar degree of shift of the serotonin
dose-response curve as that produced by a maximally effective
dose of ketanserin (which is reported to have approximately
70-fold less binding affinity for 5-HT1 than 5-HT2 receptors;
Hoyer et a!., 1985). The small degree of additional blockade by
increasing the dose ofketanserin to 3 mg/kg or by combinations
of ketanserin and mianserin of responses to 5-methoxytryptam-
me suggests that 5-HT1 blockade by LY53857 also cannot
explain the quantitative difference in antagonism of this ago-
nist. In addition, the similar magnitudes of shift by LY53857
and ketanserin of the dose-response curves to 5-CT and
TFMPP further indicate that the quantitative difference in
blockade of the agonists noted above is not related to a differ-
ential degree of 5-HT1-like receptor blockade by the two antag-
onists. Whether the well-known a’pha adrenergic receptor an-
tagonist properties of ketanserin (Van Nueten et at., 1981)
contributed to the smaller magnitude of antagonism of sero-
tonin is not now known.
The abilities of thiorphan to potentiate and of capsaicin
pretreatment to inhibit certain agomsts implicate the involve-
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ment of neuropeptides released from sensory neurons (capsai-
cm-sensitive C-fibers) in the abilities of these agonists to cause
decreases in GL in the guinea pig. The receptors involved in
this action appear to be 5-HT1-like and of the 5-HT3 subtype
since responses to TFMPP (in the presence of 5-HT2 blockade)
and 2-methyl-serotonin were substantially altered by capsaicin
pretreatment. Also, blockade by zacopride of responses to se-
rotonin after thiorphan administration supports 5-HT3 recep-
tor involvement in a neuropeptide release-mediated compo-
nent. This interpretation is supported by observations that
sensory neurons can be activated by serotonin (Higashi and
Nishi, 1982; Neto, 1978; Paintal, 1955; Sampson and Jaffe,
1975; Wallis et at., 1982) via 5-HT3 receptors (Christian et at.,
1989; Round and Wallis, 1986) that may be found on capsaicin-
sensitive neurons (Hamon et at., 1989) and result in release of
endogenous tachykinins (Chahl, 1983). Capsaicin-sensitive re-
sponses to serotonin have also been reported in the guinea-pig
isolated pulmonary artery (Buckner et at., 1987) and atria
(Bernoussi and Rioux, 1989) as well as in rat vascular (Arvier
et aL, 1977; Khalil and Helme, 1989) and cardiovascular actions
ofthe indoleamine (Makara et aL, 1967). The effect of capsaicin
in the present studies is not nonspecific or related to alteration
of tachykinin receptors since responses to 5-methoxytryptam-
me, a-methyl-serotonin, substance P and neurokinin A were
unaltered by this pretreatment.
A capsaicin-resistant, zacopride-insensitive pulmonary effect
may also involve serotonin-induced release of some endogenous
peptide(s). The existence of this component is suggested by
observations that, after capsaicin pretreatment and in the
presence of LY53857, serotonin-induced decreases in GL can
still be potentiated by thiorphan. Furthermore, responses to 5-
methoxytryptamine were potentiated by thiorphan (in the pres-
ence of LY53857) and unaltered by capsaicin pretreatment.
Since these effects of5-methoxytryptamine were obtained after
a maximally effective dose of LY53857 and the agonist was not
antagonized by zacopride under these conditions, the receptor
involved in this action cannot be readily classified. Insensitivity
of 5-methoxytryptamine to capsaicin pretreatment would ex-
dude an involvement of the receptor(s) activated by TFMPP.
A 5-HT3 receptor-mediated component also appears to remain
after capsaicin pretreatment since decreases in GL (albeit small
in magnitude) could still be elicited by 2-methyl-serotonin, and
zacopride caused antagonism of responses to serotonin in the
presence of LY53857 and thiorphan. Afferent pathways with
selective sensitivities to either capsaicin or serotonin and ac-
cessed by the systemic circulation have been described (Mitch-
ell et at., 1984) and might contribute to capsaicin-resistant
responses observed in this study.
Even though activation of several of the putative serotonin
receptors appears to be capable of eliciting decreases in GL in
the guinea pig, the specific localization of each remains to be
determined. Extra-pulmonary, as well as pulmonary, sites of
action are possible in the complex in vivo environment. Not-
withstanding our use of substance P and neurokinin A as
agonists representative of those known to be contained in
pulmonary C-fibers and to be substrates for NEP, other neu-
ropeptides that fulfill these criteria could also be involved in
serotonin-mediated pulmonary responses. In any case, the con-
sistent ineffectiveness, or minor degree of blockade by atropine,
indicates that serotonin receptor-mediated bronchoconstriction
in the guinea pig, under conditions of these studies, cannot, in
the main, be attributed to the activation of reflexes involving
the action of acetylcholine at muscarmnic receptors. Despite the
small degree of antagonism by pyrilamine of responses to large
doses of a-methyl-serotonin, histamine release (Feldberg and
Smith, 1953) also does not appear to be a major indirect
component of the airway responses evoked in these studies.
Other potential indirect mechanisms modulating or mediating
bronchoconstriction resulting from serotonin receptor activa-
tion remain to be explored.
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